- Home
- TENB vs OCS Comparison
TENB vs OCS Comparison
Compare TENB & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | OCS |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TENB | OCS |
|---|---|---|
| Price | $25.43 | $28.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | $31.69 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 3.3M | 449.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.23 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $999,405,000.00 | N/A |
| Revenue This Year | $9.37 | $466.06 |
| Revenue Next Year | $7.04 | $479.73 |
| P/E Ratio | $2,522.00 | ★ N/A |
| Revenue Growth | ★ 11.04 | N/A |
| 52 Week Low | $15.73 | $16.00 |
| 52 Week High | $35.69 | $34.48 |
Technical Indicators
Market Signals| Indicator | TENB | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 75.51 | 46.06 |
| Support Level | $22.03 | $25.95 |
| Resistance Level | $30.79 | $28.98 |
| Average True Range (ATR) | 1.23 | 1.64 |
| MACD | 0.40 | -0.29 |
| Stochastic Oscillator | 90.77 | 13.02 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.